MID2抗体—艾普蒂

+ +

•  

   

     The image is immunohistochemistry of paraffin-embedded Human thyroid cancer tissue using P10583(MID2 Antibody) at dilution 1/95. (Original magnification: ×200)    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human gastric cancer tissue using P10583(MID2 Antibody) at dilution 1/95. (Original magnification: ×200)    

  
  

MID2 (Midline-2), also known as TRIM1 (Tripartite Motif-containing Protein 1), is a member of the TRIM protein family characterized by conserved RING, B-box, and coiled-coil domains. Initially identified for its role in developmental processes, MID2 is an E3 ubiquitin ligase involved in the ubiquitin-proteasome system, regulating protein degradation and cellular processes like proliferation, differentiation, and apoptosis. It localizes to microtubules and interacts with cytoskeletal components, suggesting a role in maintaining cell structure and polarity.

MID2 gained attention due to its functional overlap with MID1. a related protein linked to Opitz syndrome, a genetic disorder affecting midline development. While MID1 mutations are directly associated with the syndrome, MID2 is thought to compensate for MID1 loss in some cellular contexts, though its exact biological relevance remains under investigation. Studies implicate MID2 in neurodevelopment, cancer, and immune regulation. For example, it is overexpressed in neuroblastoma and ovarian cancer, where it may promote tumor progression by modulating signaling pathways like mTOR or NF-κB.

Antibodies targeting MID2 are essential tools for studying its expression, localization, and interactions. They are widely used in techniques such as Western blotting, immunofluorescence, and immunoprecipitation. Recent research also explores MID2's potential as a therapeutic target, particularly in cancers with dysregulated ubiquitination pathways. Despite progress, further studies are needed to fully elucidate its mechanisms and disease associations.